Hypoxaemia in the early stage of COVID-19: prevalence of physical or biochemical factors?
- PMID: 36130788
- PMCID: PMC9724909
- DOI: 10.1183/16000617.0138-2022
Hypoxaemia in the early stage of COVID-19: prevalence of physical or biochemical factors?
Abstract
The ventilation–perfusion mismatch can't explain the high PaCO2–PETCO2 gap in the setting of COVID-19 induced hypoxaemia and cannot be considered as the sole pathophysiological basis for the treatment in the early stage of COVID-19
Conflict of interest statement
Conflicts of interest: G. Harutyunyan has nothing to disclose. Conflict of interest: R.I. Benitez Bermejo has nothing to disclose. Conflicts of interest: V. Harutyunyan has nothing to disclose. Conflicts of interest: G. Harutyunyan has nothing to disclose. Conflicts of interest: A. Sánchez Gimeno has nothing to disclose. Conflicts of interest: A. Cherkezyan has nothing to disclose. Conflicts of interest: S. Petrosyan has nothing to disclose. Conflicts of interest: A. Gnuni has nothing to disclose. Conflicts of interest: S. Soghomonyan has nothing to disclose.
Comment on
-
Hypoxaemia in COVID-19: many pieces to a complex puzzle.Eur Respir Rev. 2022 Jun 28;31(164):220090. doi: 10.1183/16000617.0090-2022. Print 2022 Jun 30. Eur Respir Rev. 2022. PMID: 35768129 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous